Michael Untch

Jan 13, 2025 | mims.com | Michael Untch

Patients HER2-positive (HER2+) breast cancer (BC) who achieve pathological complete response (pCR) have significantly better event-free survival (EFS), yet pCR cannot overcome the prognostic impact of baseline tumour size and nodal status.

Sep 16, 2024 | high5oncology.tv | Michael Untch |Sara M. Tolaney |Diana Lüftner

eBC - 100 seconds Endocrine therapy in triple-positive premenopausal patients Survival benefit reported with Pembro Registry data from France - no break in endocrine therapy in young patients CDK4/6i - 100 Seconds Ribociclib in younger patients Evaluation of the patient collective under 40 years Varia Compliance is everything aBC - 100 Seconds Akt-inhibition works with HR+ but not with mTNBC No benefit of Akt-inhibition in mTNBC TILs and overall suvivial in the shortHER trial aBC - 100...

Aug 7, 2024 | cancernetwork.com | Chiun-Sheng Huang |Miguel Cabral Martin |Miguel Martín |Sherene Loi |Michael Untch

BackgroundInterim results from the phase 3 NATALEE trial showed that ribociclib added to standard-of-care adjuvant nonsteroidal aromatase inhibitor (NSAI) had a significant invasive disease-free survival (iDFS) benefit in patients with stage II/III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with node-negative disease. We present the final protocol-specified analysis of iDFS (primary end point).